Paediatric Respiratory Reviews
Volume 4, Issue 1 , Pages 21-27 , March 2003

Current strategies in the prevention of respiratory syncytial virus disease

  • B.A Paes

      Affiliations

    • Corresponding Author InformationCorrespondence to: B. A. Paes. Tel.: +1-905-521-2100

References 

  1. Howard TS, Hoffman LH, Stang PE, Simoes EA. Respiratory syncytial virus pneumonia in the hospital setting: length of stay, charges and mortality. J. Pediatr. 2000;137:227–232
  2. Shay DK, Holman RC, Newman RD. Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA. 1999;282:1440–1446
  3. Centers for Disease Control and Prevention. Respiratory syncytial virus activity – United States, 1999–2000 season. MMWR Morb Mortal Wkly Rep 2000; 49: 1091–1093.
  4. Joffe S, Ray GT, Escobar GJ, Black SB, Lieu TA. Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics. 1999;104:419–427
  5. Marchetti A, Lau H, Magar R, Wang L, Devercelli G. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings. Clin. Ther. 1999;21:752–766
  6. Langley JM, Wang EE, Law BJ, et al.  Economic evaluation of respiratory syncytial virus infection in Canadian children: Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J. Pediatr. 1997;131:113–117
  7. Clark SJ, Beresford MW, Subhedar NV, Shaw NJ. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch. Dis. Child. 2000;83:313–316
  8. Carbonell-Estrany X, Quero J and the IRIS Study Group. RSV hospitalization rates in premature infants born over two consecutive seasons. Pediatr Infect Dis J 2001; 20: 874–879.
  9. Lanari M, Giovannini M, Giuffre L et al. Epidemiological survey on Italian infants hospitalized with lower respiratory tract infections: role of respiratory syncytial virus. Abstract presented at the 5th World Congress of Perinatal Medicine, 23–27 September 2001, Barcelona, Spain.
  10. Law BJ, Carbonell-Estrany X, Simoes EAF. An update on respiratory syncytial virus epidemiology: a developed country perspective. Respir. Med. 2002;96(Suppl. B):S1–S7
  11. Arnold SR, Wang EE, Law BJ, et al.  Variable morbidity of respiratory syncytial virus infection in patients with underlying lung disease: a review of the PICNIC RSV data base. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr. Infect Dis. J. 1999;18:866–869
  12. Wang EE, Law BJ, Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory infection. J. Pediatr. 1995;126:212–219
  13. Aujard Y, Fauroux B. Risk factors for severe respiratory syncytial virus infection in infants. Respir. Med. 2002;96(Suppl. B):S9–S14
  14. Carbonell-Estrany X, Quero Jimenez J. Guidelines for respiratory syncytial virus prophylaxis. An Esp. Pediatr. 2002;56:334–336
  15. Meert K, Heidemann S, Abella B, Sarnaik A. Does prematurity alter the course of respiratory syncytial virus infection?. Crit. Care Med. 1990;18:1357–1359
  16. McConnochie KM, Roghmann KJ. Parental smoking, presence of older siblings and family history of asthma increase risk of bronchiolitis. Am. J. Dis. Child. 1986;140:806–812
  17. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants <32 weeks gestation. Pediatrics. 1991;88:527–532
  18. Lowther SA, Shay DK, Holman RC, et al.  Bronchiolitis-associated hospitalizations among American Indian and Alaska Native Children. Pediatr. Infect Dis. J. 2000;19:11–17
  19. Navas L, Wang E, de Carvalho V, Robinson J. Improved outcome of respiratory syncytial virus infection in a high risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J. Pediatr. 1992;121:348–354
  20. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children 1979–1997. J. Infect. Dis. 2001;183:16–22
  21. Loscertales MP, Roca A, Ventura PJ, et al.  Epidemiology and clinical presentation of respiratory syncytial virus infection in a rural area of southern Mozambique. Pediatr. Infect. Dis. J. 2002;21:148–155
  22. Weber MW, Mulholland EK, Greenwood BM. Respiratory syncytial virus infection in tropical and developing countries. Trop. Med. Int. Health. 1998;3:268–280
  23. Carballal G, Videla C, Sequeira MD, et al.  Respiratory syncytial virus: changes in prevalence of subgroups A and B among Argentinian children 1990–1996. J. Med. Virol. 2000;61:275–279
  24. Hall CB, Walsh EE, Schnabel KC, et al.  Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J. Infect. Dis. 1990;162:1283–1290
  25. Walsh EE, McConnochie KM, Long CE, Hall CB. Severity of respiratory syncytial virus infection is related to virus strain. J. Infect. Dis. 1997;175:814–820
  26. Hall CB, Douglas RG, Geiman JM. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. J. Pediatr. 1976;89:11–15
  27. Hall CB, Douglas RJ, Geiman JM. Possible transmission by fomites of respiratory syncytial virus. J. Infect. Dis. 1980;141:98–102
  28. Hall CB, Douglas RG. Modes of transmission of respiratory syncytial virus. J. Pediatr. 1981;99:100–103
  29. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am. J. Epid. 1969;89:405–421
  30. Kim HW, Cancholla JG, Brandt CD, et al.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epid. 1969;89:422–434
  31. Piedimonte G. New areas of research in RSV prophylaxis. Oral presentation at Current Topics in RSV symposium, 8–9 September 2000, Paris, France.
  32. Simoes EA, Tan DH, Ohlsson A, Sales V, Wang EE. Respiratory syncytial virus vaccine: a systematic overview with emphasis on respiratory syncytial virus subunit vaccines. Vaccine. 2001;20:954–960
  33. Wang EEL, Law BJ, Robinson JL, et al.  PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada). Study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease. Pediatrics. 1997;99:e9
  34. Glezen WP, Taber LH, Frank AL, Kessel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 1986;140:543–546
  35. Groothuis JR, Simoes EAF, Levin MJ, et al.  Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N. Engl. J. Med. 1993;329:1524–1530
  36. The PREVENT study group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 99: 93–99.
  37. Wang EE, Tang NK. Immunoglobulin for preventing respiratory syncytial virus infection (Cochrane Review). In: The Cochrare Library, 2000. Oxford: Update Software.
  38. Simoes EA, Sondheimer HM, Top FH, et al.  Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group. J. Pediatr. 1998;133:492–499
  39. O’Shea TM, Sevick MA, Givner LB. Costs and benefits of respiratory syncytial virus immunoglobulin to prevent hospitalization for lower respiratory tract illness in very low birth weight infants. Pediatr. Infect Dis. J. 1998;17:587–593
  40. Robbins JM, Tilford JM, Jacobs RF, et al.  A number-needed-to-treat analysis of the use of respiratory syncytial virus immune globulin to prevent hospitalization. Arch. Pediatr. Adolesc. Med. 1998;152:358–366
  41. Johnson S, Oliver C, Prince GA, et al.  Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J. Infect. Dis. 1997;176:1215–1224
  42. Young J. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Ped. Respir. Med. 2002;96(Suppl. B):S31–S35
  43. Saez-llorens X, Castano E, Null D, et al.  Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J. 1998;17:787–791
  44. Subramanian KNS, Weisman LE, Rhodes T, et al.  Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Pediatr. Infect. Dis. J. 1998;17:110–115
  45. The IMpact RSV study group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102; 531–537.
  46. Behrendt CE, Decker MD, Burch DJ, Watson PH. International variation in the management of infants hospitalized with the respiratory syncytial virus. International RSV study group. Eur. J. Pediatr. 1998;157:215–220
  47. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Paediatrics 1998; 102: 1211–1216.
  48. A joint Canadian Pediatric Society statement with the Fetus and Newborn Committee. Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants. Paediatr Child Health 1999; 4: 474–480.
  49. Simoes EAF. New therapeutic approaches in RSV infection: vaccines and prophylaxis? Oral presentation at the European Respiratory Society Meeting, 23 September 2001, Berlin, Germany.
  50. Simoes EAF, Groothuis JR. Respiratory syncytial virus prophylaxis – the story so far. Respir. Med. 2002;96(Suppl. B):S15–S24
  51. Wang EEL, Law BJ, Boucher FD, et al.  Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study of admission and management variation in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J. Pediatr. 1996;129:390–395
  52. Stevens TP, Sinkin RA, Hall CB, et al.  Respiratory syncytial virus in premature infants born at 32 weeks’ gestation or earlier: hospitalization and economic implications of prophylaxis. Arch. Pediatr. Adolesc. Med. 2000;154:55–61
  53. Law BJ, MacDonald N, Langley J, et al.  Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: what are we trying to prevent?. Paediatr. Child Health. 1998;3:402–404
  54. Miedema CJ, Kors AW, Tjon A, Ten WE, Kimpen JLL. Medical consumption and socioeconomic effects of infection with respiratory syncytial virus in the Netherlands. Pediatr. Infect Dis. J. 2001;20:160–163
  55. Schrand LM, Elliott JM, Ross MB, Bell EF, Mutnick AH. A cost–benefit analysis of RSV prophylaxis in high-risk infants. Ann. Pharmacol. 2001;35:1186–1193
  56. Farina D, Rodrigues SP, Bauer G, et al.  Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. Ped. Infect. Dis. J. 2002;21:287–291
  57. Marchetti AE, Lau H, Magar RS et al. Expected RSV-related changes for prophylaxed vs. non-prophylaxed infants at risk. Poster presentation at Advances in Prevention and Treatment of Respiratory Tract Diseases, 8–9 September 2000, Paris, France.
  58. Clark SJ, Beresford MW, Subhedar NV, Shaw NJ. Respiratory syncytial virus infection in high-risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch. Dis. Child. 2000;83:313–316
  59. Numa A. Outcome of respiratory syncytial virus infection and a cost–benefit analysis of prophylaxis. J. Paediatr. Child Health. 2000;36:422–427
  60. Tablan OC, Anderson LJ, Arden NH et al. Guideline for prevention of nosocomial pneumonia. MMWR Morb Mortal Wkly Rep 1997; 46 (RR-1).
  61. Lofland JH, O’Connor JP, Chatterton ML, et al.  Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effective analysis. Clin. Ther. 2000;22:1357–1369

PII: S1526-0542(02)00306-8

doi: 10.1016/S1526-0542(02)00306-8

Paediatric Respiratory Reviews
Volume 4, Issue 1 , Pages 21-27 , March 2003

Article Tools